Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L GABRILOVE

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|October 1, 1988
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urotheliumJ L Gabrilove, A Jakubowski, K Fain, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factorG C Toner, J L Gabrilove, M Gordon, et al.
Blood|August 26, 1998
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent mannerZ G Wang, R Rivi, L Delva, et al.
Journal of Biological Response Modifiers|August 1, 1987
Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2J E Kolitz, K Welte, G Y Wong, et al.
Blood Cells|January 1, 1987
Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesisK Welte, M A Bonilla, J L Gabrilove, et al.
The Journal of Experimental Medicine|April 1, 1987
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primatesK Welte, M A Bonilla, A P Gillio, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancerP B Chapman, T J Lester, E S Casper, et al.
The New England Journal of Medicine|June 2, 1988
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urotheliumJ L Gabrilove, A Jakubowski, H Scher, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|October 1, 1988
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urotheliumJ L Gabrilove, A Jakubowski, K Fain, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factorG C Toner, J L Gabrilove, M Gordon, et al.
Blood|August 26, 1998
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent mannerZ G Wang, R Rivi, L Delva, et al.
Journal of Biological Response Modifiers|August 1, 1987
Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2J E Kolitz, K Welte, G Y Wong, et al.
Blood Cells|January 1, 1987
Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesisK Welte, M A Bonilla, J L Gabrilove, et al.
The Journal of Experimental Medicine|April 1, 1987
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primatesK Welte, M A Bonilla, A P Gillio, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancerP B Chapman, T J Lester, E S Casper, et al.
The New England Journal of Medicine|June 2, 1988
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urotheliumJ L Gabrilove, A Jakubowski, H Scher, et al.
Pageof 8